



Cannabis Use Outcomes for Clinical Trials (CUOCT)

March 23, 2018

AGENDA

This meeting is focused upon an assessment of measures used in clinical trials that have studied the treatment of persons with cannabis use disorder. The meeting's intent is not to examine measures related to the use of cannabis as a therapeutic agent.

The goals of this meeting are to:

1. Discuss the findings from a systematic review of cannabis use measures utilized in clinical trials for cannabis use disorder (CUD);
2. Determine if there are current use measures that are promising, or if new measures are needed;
3. Discuss outcomes linked to use measures, and
4. Identify data gaps that need to address the finalization of a standard use measure for CUD.

7:15 AM – 8:00 AM	Breakfast	Oakley Room
8:00 AM - 8:15 AM	Welcome Introductions, goals of meeting	Linden Oak Room Eric Strain, MD Robert Dworkin, PhD Dennis Turk, PhD
8:15 AM - 8:45 AM	Findings from a systematic review of cannabis use measures	Dustin Lee, PhD

Determining a standardized approach for measuring cannabis use

8:45 AM - 9:05 AM	Strengths and limitations of biologic assays for cannabis use	Marilyn Huestis, PhD
9:05 AM - 9:25 AM	Challenges in obtaining accurate self-report assessments of cannabis use	Frances Levin, MD
9:25 AM - 9:45 AM	Measuring cannabis use severity	Deborah Hasin, PhD
9:45 AM - 10:15 AM	Group Discussion	
10:15 AM - 10:30 AM	Break	

Cannabis use as a treatment outcome: what is optimal to determine treatment efficacy

10:30 AM - 10:50 AM	Overview of substance use outcomes in other SUD trials (e.g., tobacco, alcohol, stimulants)	Brian Kiluk, PhD
---------------------	--	------------------



Cannabis Use Outcomes for Clinical Trials (CUOCT)

10:50 AM - 11:10 AM	Abstinence vs. reduction as a primary treatment outcome	Alan Budney, PhD
11:10 AM - 11:30 AM	Differentiating problematic non-medical use from medicinal use	Ryan Vandrey, PhD
11:30 AM - 11:50 AM	FDA Clinical Outcome Assessment (COA)	Elektra Papadopoulos, MD
11:50 AM - 12:15 PM	Group Discussion	
12:15 PM - 1:00 PM	Lunch	Oakley Room

Other primary/secondary outcome domains to potentially include in CUD trials

1:00 PM - 1:20 PM	Overview of secondary outcome domains	Erica Peters, PhD
1:20 PM - 1:40 PM	Determining a clinically-significant improvement in function	Kathleen Carroll, PhD
1:40 PM - 2:00 PM	Secondary outcomes in pharmacological vs. behavioral treatments: standardized or tailored to intervention type?	Kevin Gray, MD
2:00 PM - 2:30 PM	Group Discussion	
2:30 PM - 2:45 PM	Break	

Other relevant topics

2:45 PM - 3:05 PM	Outcomes as they relate to special populations	Denise Walker, PhD
3:05 PM - 3:25 PM	Laboratory methods for screening new medications	Joshua Lile, PhD
3:25 PM - 4:00 PM	General Discussion Wrap-up	